Rivaroxaban

證據等級: L5

預測適應症: 4 個

Rivaroxaban: From Anticoagulation Therapy to Rheumatoid Arthritis

One-Sentence Summary

Rivaroxaban is a direct Factor Xa inhibitor anticoagulant, generally used for prevention and treatment of thromboembolic conditions (e.g., venous thromboembolism, stroke prevention in atrial fibrillation); no structured original-indication data is present in this dataset. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 0 clinical trials and 4 publications currently identified — none of which directly test rivaroxaban as an RA therapy.

Quick Overview

Item	Content
Original Indication	Not available in current dataset (drug not marketed in Finland; known generally as an anticoagulant/Factor Xa inhibitor)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.57%
Evidence Level	L4
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, rivaroxaban is a direct Factor Xa inhibitor used to prevent and treat thromboembolic disease; it has no established mechanistic action on inflammatory or immune pathways.

Rheumatoid arthritis (RA) is a chronic inflammatory disease, and elevated inflammatory activity is known to increase venous thromboembolism (VTE) risk. In clinical practice, RA patients may receive rivaroxaban to manage a co-occurring VTE or atrial fibrillation event — that is, treatment of a complication of RA, not RA itself.

There is no evidence that Factor Xa inhibition acts on RA's core inflammatory pathways (e.g., TNF-α, IL-6). The high TxGNN score most likely reflects an indirect knowledge-graph association driven by RA–VTE comorbidity co-occurrence rather than a genuine therapeutic mechanism, and should be interpreted with caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29621248	2018	Cohort	PloS one	Compares medication adherence between rivaroxaban and apixaban in non-valvular atrial fibrillation patients; not RA-specific.
33141212	2020	Review	JAMA	General review of lower-extremity VTE diagnosis and treatment; does not address RA.
34175144	2021	Review	La Revue de medecine interne	Discusses thrombin generation assay for assessing hypercoagulability in autoimmune disease (e.g., antiphospholipid syndrome); RA relevance is indirect.
41918541	2026	Case Report	Cureus	Case of an 88-year-old woman with RA (on oral steroids) and atrial fibrillation who had recurrent thromboembolic events despite anticoagulation — illustrates RA as a comorbidity in anticoagulated patients, not RA treatment.

Finland Market Information

Rivaroxaban is currently not marketed in Finland (0 authorizations on record); no license data is available.

Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA/Fimea package insert warnings and contraindications are a blocking data gap for this candidate — see Next Steps.)

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN score, there is no clinical trial evidence and no mechanistic support for rivaroxaban treating RA itself — the identified literature reflects RA-as-comorbidity in anticoagulated patients rather than RA-directed efficacy. Combined with the absence of safety/regulatory data, this candidate does not meet the bar to proceed.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — currently a blocking gap preventing initial safety assessment
DrugBank-sourced mechanism of action data
RA-specific mechanistic or preclinical studies (e.g., effect of Factor Xa inhibition on synovial inflammation) to distinguish a true signal from comorbidity-driven graph noise

Other candidates from this evidence pack (gout, HIV infectious disease, brachydactyly-syndactyly syndrome) were also evaluated and all received a Hold recommendation, with weaker or no mechanistic rationale than rheumatoid arthritis.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.